环磷酰胺治疗结缔组织病相关间质性肺疾病的疗效
Efficacy of cyclophosphamide in treating connective tissue disease-related interstitial lung diseases.
作者信息
Nucera Valeria, Gerratana Elisabetta, Giallanza Manuela, La Corte Laura, Sangari Donatella, Atzeni Fabiola
机构信息
Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Messina, Italy.
出版信息
Drugs Context. 2021 Jan 15;10. doi: 10.7573/dic.2020-9-1. eCollection 2021.
Interstitial lung diseases (ILDs) are some of the first and most serious complications of connective tissue diseases (CTDs). However, the pathogenesis of CTD-related ILDs (CTD-ILDs) is still unclear and their treatment often depends on functional and radiographic disease progression as well as on patient age and comorbidities. It can be difficult to manage CTD-ILDs due to their heterogeneous nature, the lack of robust therapeutic data, and the few well-defined outcome measures. This review focuses on cyclophosphamide due to its crucial role in the treatment of systemic sclerosis-related ILD, particularly in the case of patients with progressive ILD. This narrative review was performed using PubMed, Medline, and Cochrane Library databases to retrieve English language papers published between 2000 and April 2020 concerning the treatment of CTD-ILDs with cyclophosphamide.
间质性肺疾病（ILDs）是结缔组织病（CTDs）最早出现且最为严重的并发症之一。然而，CTD相关ILDs（CTD-ILDs）的发病机制仍不明确，其治疗通常取决于功能和影像学上的疾病进展以及患者年龄和合并症。由于CTD-ILDs具有异质性、缺乏有力的治疗数据以及明确的预后指标较少，因此其管理颇具难度。本综述聚焦于环磷酰胺，因其在系统性硬化症相关ILD的治疗中起着关键作用，尤其是在进行性ILD患者中。本叙述性综述使用PubMed、Medline和Cochrane图书馆数据库检索了2000年至2020年4月期间发表的关于用环磷酰胺治疗CTD-ILDs的英文论文。
Zotero 插件